Single‐blind follow‐up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome

Wiley - Tập 5 Số 4 - Trang 169-174 - 2004
J Tsuchiya1,2, Rafael Del Orbe2, Ruichi Okura2, Shichiro Kawakita2, E. Fesce3, Francesco Marotta3
1Biokenkyujo Research Laboratory, Shizuoka, Japan
2TMC Hospital
3Hepato-GI Department, S. Giuseppe Hospital, Milano, Italy

Tóm tắt

OBJECTIVE:  Experimental and clinical studies have shown that a novel symbiotic (known as SCM‐III) exerts a beneficial effect on gut translocation and local and systemic inflammatory and microbial metabolic parameters. The present investigation was a preliminary trial on the effectiveness of SCM‐III for irritable bowel syndrome (IBS).METHODS:  Sixty‐eight consecutive adult patients with IBS who were free from lactose malabsorption, abdominal surgery, overt psychiatric disorders and ongoing psychotropic drug therapy or ethanol abuse were studied prospectively and divided into 2 groups that were comparable for age, gender, body size, education and pattern of presenting symptoms. The 2 groups were blindly given for 12 weeks either SCM‐III 10 mL t.i.d or the same dosage of heat‐inactivated symbiotic.RESULTS:  Treatment with SCM‐III was ‘effective’ or ‘very effective’ in more than 80% of the patients (P < 0.01 vs baseline values and control). Less than 5% reported ‘not effective’ as the final evaluation compared with over 40% of patients in the control group. After 6 weeks of treatment, a significant improvement of pain and bloating was reported in the treatment group compared with control and baseline values. There was also a benefit for bowel habits, mostly for patients with constipation or alternating bowel habits. No overt clinical or biochemical adverse side‐effects were recorded.CONCLUSION:  Compared with baseline values and the control group, SCM‐III resulted in a significant increase in lactobacilla, eubacteria and bifidobacteria, which suggests that some selected IBS patients could benefit substantially from symbiotics, but the treatment may need to be given on a cyclic schedule because of the temporary modification of the fecal flora.

Từ khóa


Tài liệu tham khảo

Thompson WG, 1999, Functional bowel disorders and functional abdominal pain, Gut, 45, 43, 10.1136/gut.45.2008.ii43

10.1016/0016-5085(95)90373-9

10.1007/BF01318114

10.1056/NEJM197804202981604

10.1136/gut.48.1.20

10.1046/j.1365-2036.1999.00610.x

Humphrey PP, 1999, The therapeutic potential of 5‐TH3 receptor antagonists in the treatment of irritable bowel syndrome (review article), Aliment Pharmacol Ther, 13, 31, 10.1046/j.1365-2036.1999.00003.x-i2

10.1046/j.1365-2036.1998.00375.x

10.1046/j.1365-2036.2000.00786.x

10.1007/s11938-003-0020-y

10.1016/S1590-8658(02)80164-5

10.1111/j.1572-0241.2000.02015.x

10.1016/S0140-6736(87)93078-9

10.3109/07853899009147243

10.1056/NEJM199511163332016

10.3109/07853899009147242

Isolauri E, 1991, A human Lactobacillus strain (L. casei GG) promotes recovery from acute diarrhoea in children, Pediatrics, 88, 90

10.1097/00042737-200110000-00004

10.1046/j.1443-9573.2002.00095.x

10.1093/jn/125.6.1401

Barreto R, 2000, Gut flora manipulation mitigates ethanol‐induced liver damage and endotoxinemia: experimental comparison between a novel probiotic and metronidazole, Intern Med J, 7, 121

Marotta F, 2004, Chemopreventive effect of a probiotic preparation on the development of preneoplastic and neoplastic colonic lesions: an experimental study, Hepatogastroenterology, 50, 19148

10.1046/j.1443-9573.2003.t01-4-.x

10.1046/j.1443-9611.2003.00110.x

Drossman DA, 1999, The functional gastrointestinal disorders and the Rome II process, Gut, 45, 1

10.1111/j.1753-4887.1998.tb01665.x

10.1111/j.1572-0241.1999.01077.x

10.1093/ajcn/67.4.710

Mitsuoka T, 1976, The fecal flora of man: Comparison of the newly developed method with the old conventional method for the analysis of intestinal flora, Zentralb Bakteriol, 234, 219

10.1155/1999/240329

10.1046/j.1365-2036.2002.01305.x

10.1136/gut.48.2.272

Jones J, 2000, British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome, Gut, 47

McFarland LV, 1995, Biotherapeutic agents: past, present and future, Microecol Ther, 23, 46

10.1016/S0958-1669(02)00365-8

10.1079/BJN2002628

Balsari A, 1982, The fecal microbial population in the irritable bowel syndrome, Microbiologica, 5, 185

10.1016/S0923-2508(01)01254-2

10.1016/j.hepres.2003.11.005

10.1016/S0958-6946(98)00073-9

10.1016/S1590-8658(02)80164-5

10.1046/j.1365-2036.1999.00560.x

10.1053/gast.2000.9370

Thông tin
Thông tin xuất bản

Wiley

Tập 5 Số 4

169-174

Thông tin tác giả